This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (60)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA  Topic Collections  • Viral Infections  • Sexually Transmitted Diseases  • Dermatology  • Dermatologic Disorders  • Herpes  • Infectious Diseases  • Alert me on articles by topic  Social Bookmarking   What's this?

A Randomized Controlled Trial

Francisco Diaz-Mitoma, MD, PhD; R. Gary Sibbald, MD; Stephen D. Shafran, MD; Ron Boon; Robin L. Saltzman, MD; for the Collaborative Famciclovir Genital Herpes Research Group

JAMA. 1998;280:887-892.

Context.— Recurrent genital herpes simplex virus (HSV) may be treated episodically, but this may not be sufficient for patients with frequent recurrences.

Objective.— To determine the efficacy and safety of famciclovir in the suppression of recurrent genital HSV infection.

Design.— A randomized, double-blind, placebo-controlled, parallel-group study.

Setting.— Thirty university, hospital, or private outpatient referral centers in Canada and Europe.

Patients.— A total of 455 patients (223 men, 232 women) aged 18 years or older with a history of 6 or more episodes of genital herpes during 12 of the most recent 24 months, in the absence of suppressive therapy, received study medication.

Intervention.— Oral famciclovir, 125 mg or 250 mg 3 times daily or 250 mg twice daily, or placebo for 52 weeks.

Main Outcome Measures.— Time to the first recurrence of genital HSV infection; the proportion of patients remaining free of HSV recurrence at 6 months; frequency of adverse events.

Results.— In an intent-to-treat analysis, famciclovir significantly delayed the time to the first recurrence of genital herpes at all dose regimens (hazard ratios, 2.9-3.3;P< .001); median time to recurrence for famciclovir recipients was 222 to 336 days compared with 47 days for placebo recipients. The proportion of patients remaining free of HSV recurrence was approximately 3 times higher in famciclovir recipients (79%-86%) than in placebo recipients (27%) at 6 months (relative risks, 2.9-3.1;P <.001); efficacy was maintained at 12 months. Famciclovir was well tolerated with an adverse experience profile comparable to placebo.

Conclusions.— Oral famciclovir (125 mg or 250 mg 3 times daily or 250 mg twice daily) is an effective, well-tolerated treatment for the suppression of genital HSV infection in patients with frequent recurrences.

From the Children's Hospital of Eastern Ontario, Ottawa (Dr Diaz-Mitoma), and the Women's College Hospital, Toronto, Ontario (Dr Sibbald); the Division of Infectious Diseases, Department of Medicine, University of Alberta, Edmonton (Dr Shafran); SmithKline Beecham Pharmaceuticals, New Frontiers Science Park, Harlow, England (Mr Boon); and SmithKline Beecham Pharmaceuticals, King of Prussia, Pa (Dr Saltzman).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Long-term Suppression of Genital Herpes
Jeffrey P. Engel
JAMA. 1998;280(10):928-929.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Use of the designation "shedder" in mucosal detection of herpes simplex virus DNA involving repeated sampling
Magaret et al.
Sex. Transm. Infect. 2009;85:270-275.
ABSTRACT | FULL TEXT  

The Treatment of Herpes Simplex Infections: An Evidence-Based Review
Cernik et al.
Arch Intern Med 2008;168:1137-1144.
ABSTRACT | FULL TEXT  

Patient satisfaction with care for genital herpes: insights from a global survey
Patrick et al.
Sex. Transm. Infect. 2004;80:192-197.
ABSTRACT | FULL TEXT  

Herpes Simplex Virus Resistance to Acyclovir and Penciclovir after Two Decades of Antiviral Therapy
Bacon et al.
Clin. Microbiol. Rev. 2003;16:114-128.
ABSTRACT | FULL TEXT  

A Review of Antiviral Therapy for Herpes Labialis
Vander Straten et al.
Arch Dermatol 2001;137:1232-1235.
FULL TEXT  

Effect of Famciclovir on Herpes Simplex Virus Type 1 Corneal Disease and Establishment of Latency in Rabbits
Loutsch et al.
Antimicrob. Agents Chemother. 2001;45:2044-2053.
ABSTRACT | FULL TEXT  

Antiviral Therapies for Long-term Suppression of Genital Herpes
Wald et al.
JAMA 1999;281:1169-1170.
FULL TEXT  

Oral Famciclovir for Suppression of Recurrent Genital Herpes Simplex
Journal Watch Dermatology 1998;1998:7-7.
FULL TEXT  

Another Antiviral Agent for Suppression of Genital Herpes: Famciclovir
JWatch Infect. Diseases 1998;1998:4-4.
FULL TEXT  

Famciclovir Effectively Suppresses Recurrent Genital Herpes
JWatch Women's Health 1998;1998:3-3.
FULL TEXT  

Long-term Suppression of Genital Herpes
Engel
JAMA 1998;280:928-929.
FULL TEXT